Does RISANKIZUMAB-RZAA Cause Product distribution issue? 31 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 31 reports of Product distribution issue have been filed in association with RISANKIZUMAB-RZAA. This represents 0.1% of all adverse event reports for RISANKIZUMAB-RZAA.
31
Reports of Product distribution issue with RISANKIZUMAB-RZAA
0.1%
of all RISANKIZUMAB-RZAA reports
0
Deaths
4
Hospitalizations
How Dangerous Is Product distribution issue From RISANKIZUMAB-RZAA?
Of the 31 reports, 4 (12.9%) required hospitalization.
Is Product distribution issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 31 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Product distribution issue?
LENALIDOMIDE (858)
CERTOLIZUMAB PEGOL (403)
SECUKINUMAB (340)
RUXOLITINIB (301)
HUMAN IMMUNOGLOBULIN G (279)
POMALIDOMIDE (254)
RELUGOLIX (243)
VEDOLIZUMAB (150)
PIMAVANSERIN (134)
TEDUGLUTIDE (132)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Product distribution issue Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA